杜莹

杜莹女士现任红杉资本中国基金董事总经理，关注领域为医疗健康行业。在2012年加入红杉之前，杜博士于2002年创立和记黄埔医药上海有限公司并担任总裁。杜博士亦是和黄中国医药科技有限公司主要创立人及首席科技官，曾于2006年主持筹划其在英国上市;在创立和黄医药之前，杜博士曾在美国辉瑞公司全球战略收购部工作，主管全球代谢类疾病项目转让及相关兼并收购。杜博士毕业后于辉瑞公司美国中央研究院开始新药研发科研工作，曾领导不同治疗领域内的多个前期及后期药物项目研究，其中有两个药物获得批文在全球销售。

杜莹女士拥有美国辛辛那提大学生物化学博士学位。

Samantha Du Sequoia Capital China Managing Director

Samantha Du, Managing Director of Sequoia Capital China, focuses on healthcare investment. Prior to joining Sequoia in 2012, Dr. Du was the founder and CEO of Hutchison MediPharma Limited since 2001. She also co-founded Hutchison China MediTech Limited, where she acted as its CSO and played a key role in its sucessful IPO on UK Aim market. Before Hutchison MediPharma, Dr. Du worked at Pfizer US, where she was responsible for global metabolic diseases licensing on the scientific side. Samantha started her industry career at Pfizer US global R&D headquarter, where she led teams involved in drug development in various stages and therapeutic areas, two of the products she worked on had received global regulatory approval and launch.

Dr. Du received her Ph.D. in Biochemistry from University of Cincinnati. She is currently an adjunt professor at Fudan University and chairwoman of shanghai pudong drug innovation consortium. She is an recipient both of thousand talent program in shanghai and of shanghai Magnolia award. She is on the board of BGI tech, JHL biotech, Beta Pharma.